IL231351A - Imidazopyridazines are conserved in amino acids - Google Patents

Imidazopyridazines are conserved in amino acids

Info

Publication number
IL231351A
IL231351A IL231351A IL23135114A IL231351A IL 231351 A IL231351 A IL 231351A IL 231351 A IL231351 A IL 231351A IL 23135114 A IL23135114 A IL 23135114A IL 231351 A IL231351 A IL 231351A
Authority
IL
Israel
Prior art keywords
amino
substituted imidazopyridazines
imidazopyridazines
substituted
Prior art date
Application number
IL231351A
Other languages
English (en)
Hebrew (he)
Other versions
IL231351A0 (en
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47831558&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL231351(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of IL231351A0 publication Critical patent/IL231351A0/en
Publication of IL231351A publication Critical patent/IL231351A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)
  • Fats And Perfumes (AREA)
IL231351A 2011-09-06 2014-03-06 Imidazopyridazines are conserved in amino acids IL231351A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP11180129 2011-09-06
EP11182440 2011-09-23
EP12179902 2012-08-09
PCT/EP2012/067264 WO2013034570A1 (en) 2011-09-06 2012-09-05 Amino-substituted imidazopyridazines

Publications (2)

Publication Number Publication Date
IL231351A0 IL231351A0 (en) 2014-04-30
IL231351A true IL231351A (en) 2017-01-31

Family

ID=47831558

Family Applications (1)

Application Number Title Priority Date Filing Date
IL231351A IL231351A (en) 2011-09-06 2014-03-06 Imidazopyridazines are conserved in amino acids

Country Status (36)

Country Link
US (1) US9499547B2 (member.php)
EP (1) EP2758401B1 (member.php)
JP (1) JP6174583B2 (member.php)
KR (1) KR20140059268A (member.php)
CN (1) CN103958515B (member.php)
AP (1) AP2014007496A0 (member.php)
AU (1) AU2012306422B2 (member.php)
BR (1) BR112014004687A2 (member.php)
CA (1) CA2847514A1 (member.php)
CL (1) CL2014000543A1 (member.php)
CO (1) CO6900146A2 (member.php)
CR (1) CR20140113A (member.php)
CY (1) CY1119433T1 (member.php)
DK (1) DK2758401T3 (member.php)
DO (1) DOP2014000051A (member.php)
EA (1) EA025688B1 (member.php)
EC (1) ECSP14013231A (member.php)
ES (1) ES2638319T3 (member.php)
GT (1) GT201400043A (member.php)
HR (1) HRP20171248T1 (member.php)
IL (1) IL231351A (member.php)
LT (1) LT2758401T (member.php)
MA (1) MA35422B1 (member.php)
ME (1) ME02951B (member.php)
MX (1) MX348064B (member.php)
MY (1) MY168413A (member.php)
PE (1) PE20141593A1 (member.php)
PH (1) PH12014500501A1 (member.php)
PL (1) PL2758401T3 (member.php)
PT (1) PT2758401T (member.php)
RS (1) RS56179B1 (member.php)
SG (1) SG11201400219PA (member.php)
SI (1) SI2758401T1 (member.php)
UA (1) UA117092C2 (member.php)
WO (1) WO2013034570A1 (member.php)
ZA (1) ZA201402498B (member.php)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9730929B2 (en) 2011-06-01 2017-08-15 Bayer Intellectual Property Gmbh Substituted aminoimidazopyridazines
UA117092C2 (uk) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Амінозаміщені імідазопіридазини
US9320737B2 (en) * 2011-09-23 2016-04-26 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
US9643974B2 (en) 2011-12-12 2017-05-09 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines
US9777004B2 (en) 2012-03-29 2017-10-03 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines
EP2834245B1 (en) 2012-04-04 2017-12-13 Bayer Pharma Aktiengesellschaft Amino-substituted imidazopyridazines
CN104797585B (zh) 2012-11-19 2017-08-15 拜耳医药股份公司 氨基咪唑并哒嗪
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
US9200004B2 (en) 2013-01-15 2015-12-01 Incyte Holdings Corporation Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors
CN105008363A (zh) * 2013-01-30 2015-10-28 拜耳医药股份公司 作为mknk-1激酶抑制剂的酰氨基咪唑并哒嗪
HK1212699A1 (zh) * 2013-02-20 2016-06-17 拜耳医药股份公司 作为mknk1抑制剂的取代的咪唑并[1,2-b]哒嗪类化合物
PE20160532A1 (es) 2013-08-23 2016-05-21 Incyte Corp Compuesto de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim
JP2017503809A (ja) 2014-01-09 2017-02-02 バイエル・ファルマ・アクティエンゲゼルシャフト アミド置換イミダゾピリダジン
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
CN107108636A (zh) * 2014-12-23 2017-08-29 拜耳医药股份公司 6‑羟基苯并呋喃基‑和6‑烷氧基苯并呋喃基‑取代的咪唑并哒嗪
US10702526B2 (en) 2015-04-20 2020-07-07 Effector Therapeutics Inc. Inhibitors of immune checkpoint modulators and related methods
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
WO2017117052A1 (en) * 2015-12-31 2017-07-06 Effector Therapeutics, Inc. Mnk biomarkers and uses thereof
WO2017157418A1 (en) 2016-03-15 2017-09-21 Bayer Pharma Aktiengesellschaft Combination of mknk1-inhibitors
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4408047A (en) 1980-03-28 1983-10-04 Merck & Co., Inc. Imidazodiazines
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
FR2619818B1 (fr) 1987-09-01 1990-01-12 Sanofi Sa Imidazo (1,2-b) pyridazines, procede pour leur preparation et compositions pharmaceutiques les contenant
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US20040254189A1 (en) 2001-08-23 2004-12-16 Hideaki Nagaya Jnk inhibitors
US20100216798A1 (en) 2005-07-29 2010-08-26 Astellas Pharma Inc Fused heterocycles as lck inhibitors
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
DE102005042742A1 (de) 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US7750000B2 (en) 2005-09-02 2010-07-06 Bayer Schering Pharma Ag Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
WO2007033080A2 (en) 2005-09-12 2007-03-22 Emory University Alzheimer's disease imaging agents
DE102006029447A1 (de) * 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel
WO2007147874A1 (en) 2006-06-22 2007-12-27 Biovitrum Ab (Publ) Pyridine and pyrazine derivatives as mnk kinase inhibitors
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
EP1900739A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Diazolodiazine derivatives as kinase inhibitors
EP2063962A2 (en) * 2006-09-07 2009-06-03 Biogen Idec MA Inc. Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
AU2007315234A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
EP2086979B1 (en) 2006-11-06 2015-06-03 Tolero Pharmaceuticals, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
WO2008072682A1 (ja) 2006-12-15 2008-06-19 Daiichi Sankyo Company, Limited イミダゾ[1,2-b]ピリダジン誘導体
AR064420A1 (es) 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
US20110046127A1 (en) 2007-11-08 2011-02-24 Paolo Pevarello Imidazopyridazines for Use as Protein Kinase Inhibitors
WO2009086130A1 (en) 2007-12-21 2009-07-09 Wyeth Imidazo [1,2-b] pyridazine compounds as modulators of liver x receptors
JP6121991B2 (ja) * 2011-05-17 2017-04-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH Mknk1キナーゼ阻害剤としてのアミノ置換イミダゾピリダジン
US9730929B2 (en) 2011-06-01 2017-08-15 Bayer Intellectual Property Gmbh Substituted aminoimidazopyridazines
WO2012175591A1 (en) 2011-06-22 2012-12-27 Bayer Intellectual Property Gmbh Heterocyclyl aminoimidazopyridazines
AR087701A1 (es) 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
JO3192B1 (ar) 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
UA117092C2 (uk) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Амінозаміщені імідазопіридазини
US9320737B2 (en) 2011-09-23 2016-04-26 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
US9353081B2 (en) 2011-09-23 2016-05-31 Hoffmann-La Roche Inc. Bicyclic dihydroquinoline-2-one derivatives
US9643974B2 (en) 2011-12-12 2017-05-09 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines
US9777004B2 (en) 2012-03-29 2017-10-03 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines
EP2834245B1 (en) 2012-04-04 2017-12-13 Bayer Pharma Aktiengesellschaft Amino-substituted imidazopyridazines
CN104797585B (zh) 2012-11-19 2017-08-15 拜耳医药股份公司 氨基咪唑并哒嗪
CN105008363A (zh) 2013-01-30 2015-10-28 拜耳医药股份公司 作为mknk-1激酶抑制剂的酰氨基咪唑并哒嗪
HK1212699A1 (zh) 2013-02-20 2016-06-17 拜耳医药股份公司 作为mknk1抑制剂的取代的咪唑并[1,2-b]哒嗪类化合物
JP2017503809A (ja) 2014-01-09 2017-02-02 バイエル・ファルマ・アクティエンゲゼルシャフト アミド置換イミダゾピリダジン

Also Published As

Publication number Publication date
NZ622129A (en) 2016-06-24
UA117092C2 (uk) 2018-06-25
SG11201400219PA (en) 2014-03-28
HRP20171248T1 (hr) 2017-10-20
RS56179B1 (sr) 2017-11-30
DOP2014000051A (es) 2014-06-01
AU2012306422A1 (en) 2014-03-27
EP2758401A1 (en) 2014-07-30
GT201400043A (es) 2015-04-06
CY1119433T1 (el) 2018-03-07
PE20141593A1 (es) 2014-11-12
CN103958515B (zh) 2016-11-09
PH12014500501A1 (en) 2021-06-02
CA2847514A1 (en) 2013-03-14
KR20140059268A (ko) 2014-05-15
AP2014007496A0 (en) 2014-03-31
ECSP14013231A (es) 2014-04-30
US20140296231A1 (en) 2014-10-02
MX348064B (es) 2017-05-26
HK1199732A1 (en) 2015-07-17
BR112014004687A2 (pt) 2017-03-28
CL2014000543A1 (es) 2014-09-26
EP2758401B1 (en) 2017-05-31
US9499547B2 (en) 2016-11-22
AP3853A (member.php) 2016-09-30
MY168413A (en) 2018-11-09
MX2014002697A (es) 2014-04-25
ME02951B (me) 2018-07-20
DK2758401T3 (en) 2017-09-11
CR20140113A (es) 2014-05-02
PL2758401T3 (pl) 2017-11-30
CN103958515A (zh) 2014-07-30
EA201400311A1 (ru) 2014-09-30
AU2012306422B2 (en) 2017-10-26
WO2013034570A1 (en) 2013-03-14
JP2014525469A (ja) 2014-09-29
MA35422B1 (fr) 2014-09-01
PT2758401T (pt) 2017-08-30
SI2758401T1 (sl) 2017-10-30
ZA201402498B (en) 2017-09-27
IL231351A0 (en) 2014-04-30
JP6174583B2 (ja) 2017-08-02
CO6900146A2 (es) 2014-03-20
ES2638319T3 (es) 2017-10-19
LT2758401T (lt) 2017-08-25
EA025688B1 (ru) 2017-01-30

Similar Documents

Publication Publication Date Title
ZA201402498B (en) Amino-substituted mimidazopyridazines
DK3798230T3 (en) Terapeutiske antistoffer
DK2691417T4 (en) Antistof fc-varianter
EP2755962A4 (en) AZAINDAZOLES
GB201109414D0 (en) Diathermy -ionisation technique
EP2754063A4 (en) EXTENSIBILITY OF THE SMB2 PROTOCOL
EP2776444A4 (en) dihydropteridinones
AP2014007621A0 (en) 2-Thiopyrimidinones
EP2695208A4 (en) MICRO-THERMOCOUPLE
DK2770906T3 (en) Applanationstonometer
GB2512771B (en) Ablutionary fitting
GB201101727D0 (en) Obuoy
GB201100001D0 (en) TidySqueeze2
AU5026P (en) Goldstrike Agapanthus inapertus
AU5031P (en) BESYS Beschorneria yuccoides
AU5171P (en) Sunparamiho Mandevilla xamabilis
AU4540P (en) BUNNAN Baloskion tetraphyllum
AP00723S1 (en) Autorickshaw
GB201102066D0 (en) Scottscraper
GB201102013D0 (en) Aimspray easyreach
GB201102052D0 (en) Stabilearner
GB201110299D0 (en) Aerobars
GB201101931D0 (en) Kerbknight
GB201101815D0 (en) Psuc
GB201101772D0 (en) Hat-Pack

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees